


RESEARCH ARTICLE

The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events

Michael K. Hehir^{1*}, Mark Conaway², Eric M. Clark³, Denise B. Aronzon⁴, Noah Kolb¹, Amanda Kolb⁵, Katherine Ruzhansky⁶, Reza Sadjadi⁷, Eduardo A. De Sousa⁸, Ted M. Burns²

1 Department of Neurological Sciences, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America, **2** University of Virginia, Charlottesville, Virginia, United States of America, **3** University of Vermont Complex Systems Center, Burlington, Vermont, United States of America, **4** Timberlane Pediatrics, South Burlington, Vermont, United States of America, **5** Department of Family Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America, **6** Medical University of South Carolina, Charleston, South Carolina, United States of America, **7** Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States of America, **8** Mercy Clinic Neurology, Neuroscience Institute of Oklahoma City, Oklahoma City, Oklahoma, United States of America

* Michael.hehir@uvmhealth.org



OPEN ACCESS

Citation: Hehir MK, Conaway M, Clark EM, Aronzon DB, Kolb N, Kolb A, et al. (2022) The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. PLoS ONE 17(2): e0262109. <https://doi.org/10.1371/journal.pone.0262109>

Editor: Tai-Heng Chen, Kaohsiung Medical University Hospital, TAIWAN

Received: May 28, 2021

Accepted: December 18, 2021

Published: February 17, 2022

Copyright: © 2022 Hehir et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and the [Supporting Information Files](#).

Funding: This study was supported by American Academy of Neurology, American Brain Foundation, Myasthenia Gravis Foundation of America 2016-2019 (Grant No. 2016-0231) awarded to MH. The funder did not play role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

Objective

To design a physician and patient derived tool, the Adverse Event Unit (AEU), akin to currency (e.g. U.S. Dollar), to improve AE burden measurement independent of any particular disease or medication class.

Patients/Methods

A Research Electronic Data Capture (REDCap) online survey was administered to United States physicians with board certification or board eligibility in general neurology, subspecialty neurology, primary care internal medicine or family medicine, subspecialty internal medicine, general pediatrics, and subspecialty pediatrics. Physicians assigned value to 73 AE categories chosen from the Common Terminology Criteria of Adverse Events (CTCAE) relevant to neurologic disorder treatments. An online forced choice survey was administered to non-physician, potential patients, through Amazon Mechanical Turk (MTurk) to weight the severity of the same AE categories. Physician and non-physician data was combined to assign value to the AEU. Surveys completed between 1/2017 and 3/2019.

Results

363 physicians rated the 73 AE categories derived from CTCAE. 660 non-physicians completed forced choice experiments comparing AEs. The AEU provides 0–10, weighted values for the AE categories studied that differ from the ordinal 1–4 CTCAE scale. For example, CTCAE severe diabetes (category 4) is assigned an AEU score of 9. Although non-

Competing interests: The authors have read the journal's policy and have the following competing interests: MH has consulted for Alexion, Argenx, CSL Behring, and Octapharma, and EDS serves on the speaker bureau for both Alexion and CSL Behring. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Abbreviations: AE, Adverse Events; AEU, Adverse Event Unit; CTCAE, Common Terminology of Adverse Events; IRB, Institutional Review Board; MTurk, Amazon Mechanical Turk; QALY, Quality Adjusted Life Year; QOL, Quality of Life; REDCap, Research Electronic Data Capture; US, United States.

physician input changed physician assigned AEU values, there was general agreement among physicians and non-physicians about severity of AEs.

Conclusion

The AEU has promise to be a useful, practical tool to add precision to AE burden measurement in the clinic and in comparative efficacy research with neurology patients. AEU utility will be assessed in planned comparative efficacy clinical trials.

Introduction

There is increasing emphasis on adverse event(AE) burden in neurology as new treatments are approved [1–3]. AEs cost more than \$136 billion per year and add an average of 5 days to neurological hospitalizations [4–7]. AEs are important to patients and represent a barrier to treatment adherence. When structuring neurological treatment paradigms, among medications with equal efficacy, treatment decisions will be dictated by differences in AE burden, treatment burden, and cost. We remain without a practical metric to measure AEs that facilitates comparison of medications within and across different classes based on AEs alone.

The **Adverse Event Unit (AEU)** is a physician and patient weighted consensus unit, akin to currency (e.g. US dollar), designed to quantify and compare AE burden over time. Unlike previous measures, the AEU facilitates AE measurement independent of any disease or medication class, in terms of a number of AEU's that can be compared over time [8–13]. AEU scores can be combined with other outcome metrics and quality of life scores to better define the differences among treatments in comparative efficacy trials and in the clinic. Understanding AE tolerance in different neurological conditions and AEU validation against other disease metrics is planned for future studies. This manuscript describes the derivation of the AEU and potential applications for this new tool.

Methods

Development of the AEU was designed as a two-phase protocol to obtain input from physician experts and potential patients. In the first phase, US physicians assigned weight to the severity of AE associated with treatments for neurological illnesses. In the second phase, non-physician potential patients recruited through the Amazon Mechanical Turk (MTurk) service (<https://www.mturk.com>) rated the severity of the same group of AE. Data obtained from both phases was combined to generate value for the AEU. Surveys were completed between 1/2017 and 3/2019.

Standard protocol approvals, subject consent

The institutional review board (IRB) at the University of Vermont approved this protocol with a waiver of consent as all subjects were recruited anonymously through on-line surveys. Survey completion implied consent.

Physician subjects

United States physicians completed an on-line survey utilizing the secure Research Electronic Data Capture tool (REDCap) [14] hosted at University of Vermont. The target population was physicians with board certification or board eligibility in general neurology, subspecialty

neurology, primary care internal medicine or family medicine, subspecialty internal medicine, general pediatrics, and subspecialty pediatrics. These specialties were chosen to capture the broad range of physicians who provide medical care for neurological patients.

Champions (MKH, TMB, DBA, KR, NK, AK, and ED) identified at US centers recruited colleagues in their communities and at other centers through a combination of targeted emails and in person meetings with groups of physicians. The American Academy of Neurology facilitated recruitment of current and previous physician recipients of the development award that supported the current study. All respondents were encouraged to forward the survey to colleagues in the aforementioned medical specialties.

Potential patient subjects

The online survey tool, MTurk, was used to recruit potential patients to represent a sample of the general population in the United States. MTurk is a viable and validated method to collect data about clinical and social science populations [15, 16]. MTurk participants produced similar results when compared to in person university recruited populations in psychological surveys, behavioral tests, matched comparison groups, economic experiments, clinical studies, and social science studies [17–20]. In general, the MTurk participants tend to be of younger age. To sample a broad age range reflective of a typical neurology patient population, we stratified the surveys into the following available age cohorts: 25–30 years, 30–35 years, 35–45 years, 45–55 years, and greater than 55 years. The MTurk tool did not permit additional age stratification in the greater than 55 years category. Subjects were paid \$5 for survey completion.

Survey design and administration (Fig 1)

Items for analysis. The investigators (TB and MH) chose 73 AE categories relevant to medications prescribed across the field of neurology from the Common Terminology Criteria of Adverse Events (CTCAE) version 4 for analysis (Appendix 1 in [S1 File](#)) [21]. The CTCAE is a physician expert derived, widely employed, ordinal [1–5], unweighted scale commissioned by the National Cancer Institute used to measure AE in many clinical trials [21]. Although AE severity increases along the CTCAE scale, items given the same value may not be of equal burden. For example, the AE of moderate hypertension (level 3), which carries the long-term risk of cardiovascular complications, is given the same score as a high fever of <24 hours duration (level 3). The CTCAE category 5 corresponding to death was not analyzed as we are interested in assigning value to AE that can be monitored over time while a patient undergoes treatment. The finite category of death can be measured independently without weighting because death from any cause is presumably of equal importance and consequence. Under the guidance of a board certified pediatrician (DA), items to measure congenital complications were adapted from the DSM-5 definitions of intellectual disability, an epilepsy research classification of congenital abnormalities, and neural tube defect classification systems [22–25].

Physician subjects. Each physician subject was asked to assign values (0 = no significance to 10 = most significant) to a random sample of 30 AEs within and across the chosen 73 CTCAE and congenital categories of varying severities. They were asked to consider each AE independent of any one disease or treatment. Subjects were also asked to factor scores they assigned both within and across AE categories as they rated AE in the survey (Appendix 2 in [S1 File](#)). A separate pediatrician survey included all the congenital malformation AE evaluated in addition to non-congenital AE. Adult physicians also rated congenital AE. Median scores with associated interquartile ranges were calculated to assign initial value to the AEU. This method of assigning weighted values to the AE categories identified from the CTCAE was adapted from method used by members of our research team (TB and MC) in the construction




Fig 1. Study methodology.

<https://doi.org/10.1371/journal.pone.0262109.g001>

of the MG-Composite, a weighted, consensus, outcome measure validated for use in evaluating patients with myasthenia gravis [26].

Potential patient subjects. A subset of AE derived from the CTCAE and weighted by the physicians in phase 1 were converted into lay descriptions informed by Mayo Clinic descriptions of symptoms and medical conditions (<https://www.mayoclinic.org/symptoms>; <https://www.mayoclinic.org/diseases-conditions>). Potential patient friendly versions of the CTCAE have been employed in other studies [27].

Potential patient subjects reviewed pairs of AE descriptions (Table 1 and Appendix 3 in S1 File) assigned different AEU values by the physician subjects. AE pairs to review were randomly computer generated so that the compared AEs were from different AE categories and had been assigned different scores by the physician subjects. In the style of a discrete choice experiment, subjects were asked “After reviewing each pair of AE, please choose which of the two AE would be least tolerable (i.e. the most severe of the pair)” [28, 29]. They were also asked to consider: impact on quality of life (QOL), impact on life expectancy, future medical

Table 1. Example of potential patient discrete choice.

Instructions:

In this survey, you will review information about potential medication associated adverse events. You will be provided with a description of pairs of potential medication associated adverse events. Consider the side effects alone without thinking of any particular medication or disease.

After reviewing each pair of adverse events, please choose which of the two adverse events would be least tolerable (i.e. the most severe of the pair).

Consider the following in making your decisions:

1. Impact of the side effect on your quality of life

2. Impact on life expectancy

3. Risk to develop future medical complications because of this adverse event

4. How likely it might be the side effect will go away if medication is stopped

5. Other factors of importance to you

Deep Vein Thrombosis (DVT):

Deep vein thrombosis (DVT) occurs when a blood clot forms in one or more of the deep veins in your body, usually in your legs. Deep vein thrombosis can cause leg pain or swelling, but also can occur with no symptoms. Deep vein thrombosis can be very serious because blood clots in your veins can break loose and lodge in your lungs, blocking blood flow (pulmonary embolism). Treatment of DVT includes anticoagulant medications (blood thinners) and in severe circumstances, placement of a filter in your blood vessels or treatment with a clot busting medication. Blood thinner treatment increases the risk for bleeding.

Complication: (AEU 7)**

You have developed a DVT in your leg as a result of medical treatment. No complications have occurred with this DVT, such as pulmonary embolism. You require treatment with a blood thinner for at least a few months. You may have been admitted to the hospital for a short time due to this issue.

VS

Headache

Headaches may include syndromes that cause discomfort on the head including throbbing pain, stabbing pain, and numbness. Severe headaches may result in impaired physical and cognitive function. Severe headaches can impair daily function and may require treatment with medications. Drug induced headaches are likely to improve with stopping an offending medication.

Complication: (AEU 5)**

You have developed a severe headache that limits routine daily activities and self-care as a result of medical therapy. This headache lasts less than 1 week, may require a short course of pain medication (such as ibuprofen), and improves with discontinuing the offending medication. No ongoing medical therapy is required.

** Potential patient subjects were not shown the AEU value assigned by the physicians during the experiment. They are presented to illustrate that these AEs were given different weights by the physician subjects.

<https://doi.org/10.1371/journal.pone.0262109.t001>

complication risk, likelihood for AE resolution following therapy change, and other factors considered important to the subject. Potential patients were not told how the physicians weighted the AE being evaluated.

Combining physician and potential patient data. Bradley-Terry models were fit to the choices made by the potential patients using Firth's method for penalized maximum likelihood logistic regression in SAS version 9.4 [30, 31]. The Bradley-Terry model uses the paired comparisons obtained through Mturk to estimate a set of 'less preferred' parameters for the AE. These parameters have the property that, if an AE with parameter A is compared to a second AE with parameter B, we would estimate that a proportion $A / (A+B)$ of potential patients would choose the first AE as less tolerable. Once 'less preferred' parameters from potential patient choices were estimated, we created integer scores by applying K-means clustering to

Table 2. Baseline characteristics.

Variable	Potential Patients (n = 660)	Physicians (n = 363)
Sex, % (n) female	49% (325/660)	36% (129)
Age years, % (n)		NA
25–30 years	13% (79)	
31–35 years	10% (63)	
36–45 years	14% (87)	
46–55 years	11% (67)	
> 55 years	52% (314)	
Median years practice (range)	NA	12 (1–50)
Academic Practice % (n)	NA	86% (312)
Education, % (n)		
Grade 11 or below	1% (3)	NA
Completed Grade 12	36% (239)	NA
College/Above	63% (418)	NA
Ethnicity, % (n)		
Caucasian American	85% (547)	Did not ask
African American	8% (49)	
Hispanic American	4% (26)	
Asian American	3% (17)	
Native American	1% (3)	
Geographic Region United States, % (n)		
Northeast	22% (147)	31% (112)
Southeast	32% (210)	42% (152)
Midwest	18% (120)	12% (44)
Southwest	11% (73)	7% (26)
West	17% (109)	8% (30)
Medical Specialty, % (n)		
General Neurology	NA	16% (58)
Subspecialty Neurology	NA	43% (156)
Adult Primary Care	NA	17% (62)
Subspecialty Internal Medicine	NA	7% (25)
Pediatrics	NA	13% (47)
Other	NA	4% (15)

Potential patient numbers may not add to 660 because of missing values.

<https://doi.org/10.1371/journal.pone.0262109.t002>

the less preferred estimates, setting the number of clusters equal to 9 to match the range of integer scores provided by the physicians (2 to 10). Final adjustment to AEU scores was done by comparing the physician and the potential patient AEU scores. If the potential patient AEU score was greater than the physician assigned AEU, we increased the physician AEU across an entire AE category (e.g. hypertension) rating by 1. If the potential patient AEU score was less than the physician assigned AEU, we decreased the physician AEU across an entire AE category rating by 1. This method of combining physician and potential patients AEU scores was chosen to give weight to the expertise of physicians in understanding the overall short and long-term sequelae of the rated AEs. It is essential to arrive at single AEU scale to achieve the ultimate goal of developing a combined, easy to administer, best fit, weighted, consensus unit that would be feasible to administer in a clinical practice setting or clinical trial.

Results

Physician subjects

The targeted medical specialties were well represented (Table 2). The group was experienced and covered a wide geographic region. Recruited physicians had male and academic practice predominance. Primary care physicians practicing through university associated medical centers largely self-identified as in academic practice.

Potential patient subjects

The potential patient cohort represented the wide range of ages typical of neurology patients (Table 2). The variables of geographic regions in the U.S. and sex were equally represented. Potential patients with college level of education or above were overrepresented. In addition, African Americans, Hispanic Americans, and Asian Americans were slightly underrepresented when compared to most recent U.S. Census data [32].

Phase 1: Physician weighting

Three hundred sixty three physicians provided data from 397 surveys; 34 physicians completed two different surveys with different sets of AE. On a 0–10 scale (0 = no importance and 10 = maximal importance), physician responses ranged from 2–10 across the 73 AE categories evaluated. Median values with interquartile ranges are available in Appendix 1 in S1 File. In many circumstances, the weighted values provided by the physicians did not match the rigid 1–4 ordinal CTCAE scale. For example, the CTCAE category 1, corresponding to a mild AE for pulmonary fibrosis, received an AEU score of 6. The CTCAE category 4, corresponding to a severe AE for diabetes, received an AEU value of 9. In contrast, the severe CTCAE category 4 for headache received an AEU value of 6, similar to the AEU values assigned for CTCAE category 2 diabetes and CTCAE category 1 for pulmonary fibrosis.

Phase 2: Potential patient forced choice

Each of 660 MTurk potential patient raters made 20 random paired AE discrete choice comparisons. Two sets of comparisons, presented to 20 participants each, could not be used because the computer randomly assigned items with same initial physician derived AEU score. These two sets of comparisons did not allow the participants to distinguish the choices, leaving 11,463 comparisons for analysis. All 73 AE categories were used in at least one paired comparison. Appendix Table 4 in S1 File provides estimates and standard errors for the logistic regression parameters estimated using Firth's method as well as a calibration plot. The model has excellent discrimination (c-index = 0.866) and calibration. Appendix 5 in S1 File shows the

results of the K-means clustering used to assign integer scores to the preference parameters. Subsequent analyses adjusted the preference parameters for demographic characteristics, age, sex, race/ethnicity, education and region of the country and of the mTurk respondents, but none of the characteristics were statistically significant, and more importantly, did not change the final ratings. Adjustment for the demographic characteristics altered the final rating in only 3 of the 73 items, and never by more than 1 point. Given the additional complexity in interpreting the results with additional covariates, we present the final ratings based on the model without adjusting for demographic characteristics.

The AE evaluated by the potential patients ranged from 2–10 AEU points on the scale generated by the physicians and the Bradley Terry method (Table 3). Severity choice values ranged from 0.33 for a mild degree of diarrhea (physician AEU 3) to 8.5 for treatment related malignancy (physician AEU 9).

Phase 3: Combining physician and potential patient values

Final physician and potential patient combined AEU scores are presented in Table 4. Fifty-five of the 73 items were adjusted from the originally assigned physician scores to reflect input from the potential patients (Table 3). In three categories (hallucinations, dyskinesia, and thrombosis), the physician assigned AEU value of a more severe adverse event in a category had a lower score than the immediately preceding AE. For example, moderate hallucinations

Table 3. Combined physician and potential patient AEU values.

	Original AEU from physicians	AEU from potential patients' choices	Final AEU rating
Diabetes	6	8	7
Osteoporosis	4	5	5
Weight Gain 6	6	4	5
Cognitive Impairment	4	4	4
Seizure	6	7	7
Heart Attack	9	9	9
Deep Vein Thrombosis (DVT)	7	7	7
Headache	5	3	4
Hallucinations 6	6	5	5
Treatment Related Malignancy (Cancer)	9	9	9
Myalgia (Muscle Pain) 6	6	2	5
Itchy Skin (Pruritus)	6	3	5
Low Platelets	5	4	4
Low Blood Sodium (Hyponatremia)	9	6	8
Flu-Like Symptoms	2	2	2
Abnormal Movements (Dyskinesia) 4	4	5	5
Kidney Stones	7	7	7
Diarrhea	4	2	3
Pulmonary Fibrosis 9	9	9	9
Hypertension (High Blood Pressure)	4	5	5
Liver Disease	3	7	4
Kidney Failure 8	8	8	8
Infection	8	6	7
Weight Loss	8	5	7
Dizziness (Vertigo)	3	3	3
Hair Loss	5	4	4

(Continued)

Table 3. (Continued)

	Original AEU from physicians	AEU from potential patients' choices	Final AEU rating
Headache 2	2	2	2
Congestive Heart Failure	5	8	6
Stroke	10	10	10
Cataracts	5	4	4
Dry Eyes	4	3	3
Diarrhea 7	7	4	6
Suicidal Thoughts	5	7	6
Dizziness (Vertigo)	5	5	5
Pancreatitis	8	8	8
Anemia (Low Red Blood Cells)	4	4	4
INR Elevation	3	4	4
Low White Blood Cells (Neutropenia)	8	6	7
Leg and Arm Swelling (Edema)	3	4	4
Constipation	6	4	5
Headache 6	6	4	5
Glaucoma 9	9	7	8
Nausea	6	3	5
Trouble Walking	5	4	4
Allergic Reaction	5	4	4
Avascular Necrosis of a Joint	8	8	8
Glaucoma 8	8	7	7
Osteoporosis	7	6	6
Stroke 6	6	7	7
Stomach Ulcer	4	5	5
Pulmonary Fibrosis 6	6	8	7
Weight Gain 3	3	3	3
Diarrhea 3	3	2	2
Hallucinations 5	5	5	5
Abnormal Movements (Dyskinesia) 6	6	7	7
Heart Rhythm Disorder (Arrhythmia)	4	5	5
Hypertension (High Blood Pressure)	5	6	6
Kidney Failure 5	5	6	6
Myalgia (Muscle Pain) 3	3	2	2
Depression	6	5	5
Fever	6	2	5
Sexual Dysfunction	6	2	5
Anxiety	5	4	4
Mania	8	6	7
Insomnia	3	3	3
Fatigue	3	2	2
Vascular Access Complications	9	8	8
Teratogen 1	10	10	10
Teratogen 2	2	6	3
Reproductive Dysfunction	4	3	3
Urine Retention	4	3	3
Heart Failure	5	9	6
Neutropenia	8	6	7

<https://doi.org/10.1371/journal.pone.0262109.t003>

Table 4. Final values Adverse Event Unit (AEU).

Adverse Event	CTCAE 1	CTCAE 2	CTCAE 3	CTCAE 4
Chronic Illnesses				
Diabetes	<p>Pre-Diabetes: Hemoglobin A1C: 5.7–6.4% or Fasting Glucose: 100–125mg/dL or 2H Oral Gluc Tolerance Test: 140–199 mg/dL</p> <p>4</p>	<p>Diabetes Hemoglobin A1C > 6.4% or Fasting Glucose > 125mg/dL or 2H Oral Gluc Tolerance Test > 200mg/dL AND Requiring multiple medication and/or medication escalation</p> <p>6</p>	<p>Diabetes Hemoglobin A1C > 6.4% or Fasting Glucose > 125mg/dL or 2H Oral Gluc Tolerance Test > 200mg/dL AND Requiring multiple medication and/or medication escalation</p> <p>7</p>	<p>Acute Life Threatening Diabetes Hospitalization (eg Ketoacidosis)</p> <p>10</p>
Pulmonary Fibrosis	<p>Drug Related Pulmonary Fibrosis Mild Hypoxemia with Radiologic Pulmonary Fibrosis < 25% lung volume</p> <p>6</p>	<p>Drug Related Pulmonary Fibrosis Moderate Hypoxemia with Evidence of Pulmonary Hypertension OR Radiographic Evidence of Pulmonary Fibrosis 25–50% Lung Volume</p> <p>7</p>	<p>Drug Related Pulmonary Fibrosis Severe Hypoxemia Evidence of Right Side Heart Failure OR Radiographic Pulmonary Fibrosis > 50–75% Lung Volume</p> <p>9</p>	<p>Drug Related Pulmonary Fibrosis Life Threatening Consequences (e.g. hemodynamic complications) AND Intubation with Ventilatory Support</p> <p>10</p>
Hypertension	<p>Pre-Hypertension Systolic Blood Pressure: 120-139 or Diastolic Blood Pressure: 80-89</p> <p>3</p>	<p>Hypertension Systolic Blood Pressure: 140-159 or Diastolic Blood Pressure: 90-99 OR Increase or Start Anti-hypertension medications</p> <p>5</p>	<p>Hypertension Systolic Blood Pressure: > 160 or Diastolic Blood Pressure: > 100</p> <p>6</p>	<p>Life Threatening Hypertension Hospitalization for Hypertensive Urgency/ Emergency</p> <p>10</p>

(Continued)

Table 4. (Continued)

<i>Respiratory and Thoracic</i>	<i>Respiratory, Thoracic, Mediastinal Not Otherwise Specified</i> Asymptomatic or Mild Symptoms AND Clinical or Diagnostic Observations Only 3	<i>Respiratory, Thoracic, Mediastinal Not Otherwise Specified</i> Moderate, Minimal, Local, or Non-invasive Intervention Indicated AND Limiting Age Appropriate Activities Daily Living 4	<i>Respiratory, Thoracic, Mediastinal Not Otherwise Specified</i> Severe or Medically Significant but Not Life Threatening AND Hospitalization or Prolong Existing Hospitalization Disabling 8	<i>Respiratory, Thoracic, Mediastinal Not Otherwise Specified</i> Life Threatening Consequences AND Urgent Intervention Indicated 9
<i>Osteoporosis</i>	<i>Osteoporosis</i> Radiologic evidence of osteoporosis or Bone Mineral Density t score -1 to -2.5 (osteopenia) AND No intervention indicated/No loss of height 5	<i>Osteoporosis</i> Bone Mineral Density t score < -2.5 AND Anti-osteoporotic treatment indicated Limiting Activities Daily Living 5	<i>Osteoporosis</i> Radiographic osteoporosis AND Complication not requiring hospitalization (eg fracture) 7	<i>Osteoporosis</i> Radiographic osteoporosis AND Hospitalization Indicated (eg hip fracture) 8
<i>GI Ulcer</i>	<i>Gastric or Duodenal Ulcer</i> Asymptomatic AND Diagnostic Observations Only Intervention Not Indicated 5	<i>Gastric or Duodenal Ulcer</i> Symptomatic AND Altered GI Function Medical Intervention Indicated 6	<i>Gastric or Duodenal Ulcer</i> Severely Altered GI Function AND TPN Indicated OR Elective Operative or Endoscopic Intervention Indicated 9	<i>Gastric or Duodenal Ulcer</i> Life-threatening Complications AND Urgent Operative Intervention Indicated 10

(Continued)

Table 4. (Continued)

<p>Endocrine</p>	<p>Endocrine Disorders Asymptomatic or Mild Symptoms AND Clinical or Diagnostic Observations Only</p>	<p>Endocrine Disorders Moderate Symptoms AND Minimal, Local, or Non-invasive Intervention Only</p>	<p>Endocrine Disorders Severe or Medically Significant but Not Immediately Life-threatening AND Hospitalization or Prolongation of Existing Hospitalization</p>	<p>Endocrine Disorders Life-threatening Consequences AND Urgent Intervention Indicated</p>
<p>Secondary Malignancy</p>	<p>3</p>	<p>3</p>	<p>8</p>	<p>9</p>
<p>Renal Fail</p>	<p>Kidney Injury Creatinine level increase of > .3mg/dL OR Creatinine 1.5-2 times above baseline</p>	<p>Treatment Related Secondary Malignancy Non-Life Threatening Secondary Malignancy</p>	<p>Treatment Related Secondary Malignancy Chronic Life Threatening Secondary Malignancy AND Shortens Life Expectancy (e.g. Metastatic Disease)</p>	<p>Treatment Related Secondary Malignancy Acute Life Threatening Secondary Malignancy (e.g. blast crisis)</p>
<p>Congestive Heart Fail</p>	<p>Kidney Injury Creatinine 2-3 times above baseline</p>	<p>Kidney Injury Creatinine 3 times baseline or > 4mg/dL AND Hospitalization Indicated</p>	<p>Kidney Injury Creatinine 3 times baseline or > 4mg/dL AND Hospitalization Indicated</p>	<p>Kidney Injury Life-threatening consequences AND Hospitalization, dialysis, or transplant indicated</p>
	<p>5</p>	<p>5</p>	<p>8</p>	<p>10</p>
	<p>Heart Failure Asymptomatic with lab (e.g. BNP [B-natriuretic peptide]) OR Cardiac Imaging Abnormalities</p>	<p>Heart Failure Symptoms with mild to moderate activity or exertion</p>	<p>Heart Failure Severe with symptoms at rest or with minimal activity or exertion AND Intervention indicated</p>	<p>Heart Failure Life-threatening consequences AND Urgent intervention indicated(e.g. continuous IV medications, mechanical hemodynamic support</p>
	<p>6</p>	<p>6</p>	<p>10</p>	<p>10</p>

(Continued)

Table 4. (Continued)

Cardiac Arrhythmia	Atrial or Ventricular Arrhythmia Asymptomatic intervention not indicated 5	Atrial or Ventricular Arrhythmia AND Non-urgent medical intervention indicated 7	Atrial or Ventricular Arrhythmia AND Acute Medical Intervention Indicated 9	Atrial or Ventricular Arrhythmia Life-threatening Consequences AND Hemodynamic Compromise AND Hospitalization and Urgent Intervention Indicated 10
Cognitive Dysfunction	Encephalopathy or Cognitive Dysfunction Mild Symptoms AND Not Interfering with Work/School/Life Performance 4	Encephalopathy or Cognitive Dysfunction Moderate Symptoms AND Interfering with Work/School/Life Performance But Capable of Independent Living 6	Encephalopathy or Cognitive Dysfunction Severe Symptoms AND Impairing Work/School/Life Performance 9	Encephalopathy or Cognitive Dysfunction Life-Threatening Consequences AND Urgent Intervention or Hospitalization Indicated 9
Hepatic Dysfunction	Functional Hepatic Impairment Asymptomatic or Mild Symptoms AND Clinical or Diagnostic Observation Only 4	Functional Hepatic Impairment Moderate Symptoms AND Mild, Local, or Non-Invasive Intervention 6	Functional Hepatic Impairment Severe or Medically Significant but Not Immediately Life-Threatening (e.g. Mild Encephalopathy) AND Hospitalization or Prolongation of Existing Hospitalization Indicated 9	Functional Hepatic Impairment Life-Threatening Consequences (e.g. Moderate to Severe Encephalopathy, Coma, Hemorrhage) AND Hepatic Transplant and Urgent Hospitalization Indicated 10

(Continued)

Table 4. (Continued)

<i>Seizures</i>	<i>Drug Related Seizure</i>	<i>Drug Related Seizure</i>	<i>Drug Related Seizure</i>	<i>Drug Related Seizure</i>
	Brief Partial Seizure No Loss of Consciousness	Brief Generalized Seizure with Loss of Consciousness	Multiple Seizures Despite Medical Intervention	Life-Threatening Prolonged Repetitive Seizures (Status Epilepticus) AND Requiring Hospitalization and Urgent Intervention
6	7	10	10	10
<i>Glaucoma</i>	<i>Glaucoma</i> Elevated Intraocular Pressure (EIOP) without Visual Field Deficits AND Single Topical Agent Indicated	<i>Glaucoma</i> Elevated Intraocular Pressure (EIOP) with Early Visual Field Deficit AND Multiple Topical Agents and/or Oral Agent Indicated	<i>Glaucoma</i> Elevated Intraocular Pressure (EIOP) with Marked Visual Field Deficit AND Operative Intervention Indicated	<i>Glaucoma</i> Blindness in Affected Eye (20/200 or Worse)
3	5	7	8	8
<i>Cataracts</i>	<i>Cataracts</i> Asymptomatic AND Clinical or Diagnostic Observation Only	<i>Cataracts</i> Symptomatic AND Moderate Decrease in Visual Acuity (20/40 or better)	<i>Cataracts</i> Symptomatic with Marked Decrease Visual Acuity (worse than 20/40 but better than 20/ 200) AND Operative Intervention Indicated (e.g. cataract surgery)	<i>Cataracts</i> Blindness (20/200 or worse) in affected eye
2	4	6	7	7

(Continued)

Table 4. (Continued)

Acute Coronary Syndrome	Acute Coronary Syndrome Symptomatic Progressive Angina AND Cardiac Enzymes Normal Hemodynamically Stable	Acute Coronary Syndrome Symptomatic Unstable Angina OR Acute Myocardial Infarction AND Cardiac Enzymes Abnormal Hemodynamically Stable	Acute Coronary Syndrome Symptomatic Unstable Angina OR Myocardial Infarction AND Cardiac Enzymes Abnormal Hemodynamically Unstable	Acute Coronary Syndrome Life Threatening Consequences Hemodynamically Unstable AND ICU Level Care Indicated
	7	8	9	10
Stroke	Stroke Asymptomatic or Mild Neurologic Deficit Radiographic Findings Only	Stroke Moderate Neurologic Deficit	Stroke Severe Neurologic Deficit Prolonged Hospitalization AND/OR Requires Care in Long-term Facility	Stroke Life-Threatening Consequences If Survive Requires Prolonged Use of Tracheostomy AND/OR Percutaneous Gastrostomy Tube Requires Care in Long-Term Facility
	7	9	10	10
Anxiety	Anxiety Mild symptoms; intervention not indicated	Anxiety Moderate symptoms; limiting instrumental ADL	Anxiety Severe symptoms; limiting self-care ADL; hospitalization not indicated	Anxiety Life-threatening; hospitalization indicated
	1	4	6	8
Depression	Depression Mild depressive symptoms	Depression Moderate depressive symptoms; limiting instrumental ADL	Depression Severe depressive symptoms; limiting self-care ADL; hospitalization not indicated	Depression Life-threatening consequences, threats of harm to self or others; hospitalization indicated
	2	5	6	8

(Continued)

Table 4. (Continued)

Mania	Mania Mild manic symptoms (e.g., elevated mood, rapid thoughts, rapid speech, decreased need for sleep)	Mania Moderate manic symptoms (e.g., relationship and work difficulties; poor hygiene)	Mania Severe manic symptoms (e.g., hypomania; major sexual or financial indiscretions); hospitalization not indicated	Mania Life-threatening consequences, threats of harm to self or others; hospitalization indicated
Adverse Events Typically Shorter Duration	4	6	9	9
Fever	Drug Fever Temperature 38–39C (100.4–102.2F) < 24Hours 2	Drug Fever Temperature 39–40C (102.2–104F) < 24 Hours 2	Drug Fever Temperature > 40C for < 24Hours 5	Drug Fever Temperature > 40C for > 24Hours 5
Headache	Headache Mild Pain < 1 week 2	Headache Moderate Pain AND Limits Activities Daily Living < 1 week 2	Headache Severe Pain AND Limits Self Care and Activities Daily Living < 1 week 4	Chronic Headache Moderate to Severe Pain Duration > 1 week 5
Infection	Infection Asymptomatic or Mild Symptoms Diagnostic intervention only Medical intervention not indicated 1	Infection Symptomatic AND Minimal, local, or non-invasive intervention indicated 2	Infection Severe of medically significant but not immediately life threatening AND Hospitalization or prolongation existing hospitalization 7	Infection Life threatening consequences AND Urgent hospitalization or ICU level care indicated 9
Weight Gain	Weight Gain 5-10% increase from baseline 3	Weight Gain 10-20% increase from baseline 4	Weight Gain > 20% increase from baseline 6	
Weight Loss	Weight Loss 5-10% Decrease from Baseline 1	Weight Loss 10-20% Decrease from Baseline AND Requires Nutritional Support 4	Weight Loss > 20% Decrease from Baseline AND Tube feed or TPN Indicated 7	

(Continued)

Table 4. (Continued)

Thrombosis	Venous Thrombosis (e.g. superficial thrombosis)	Venous Thrombosis Uncomplicated deep vein thrombosis AND Medical Intervention Indicated 7	Uncomplicated Pulmonary Embolism or Non-embolic Cardiac Mural Thrombus AND Medical Intervention Indicated. 7	Life Threatening Thrombotic Event (e.g. Complicated Pulmonary Embolism, Arterial Insufficiency) Hemodynamic Instability AND Urgent Intervention Indicated 10
Avascular Necrosis	Avascular Necrosis Asymptomatic Clinical or Diagnostic Interventions Only 4	Avascular Necrosis Symptomatic Limiting Instrumental Activities Daily Living 6	Avascular Necrosis Severe Symptoms Limiting Self Care Activities Daily Living AND Operative Intervention Indicated 8	Avascular Necrosis Life Threatening Consequences AND Urgent Intervention Indicated 9
Hair Loss	Alopecia Hair Loss < 50% of Normal for Individual Only Noticeable from Close Inspection Different Hair Style but Doesn't Require Wig to Camouflage 3	Alopecia Hair Loss > / = 50% of Normal for Individual May be associated with Psychosocial Impact 4		
Diarrhea	Diarrhea Increase < 4 Stools Per Day Over Baseline OR Mild Increase in Ostomy Output Compared to Baseline 2	Diarrhea Increase 4–6 Stools Per Day Over Baseline Moderate Increase in Ostomy Output Compared to Baseline AND Limiting Instrumental Activities Daily Living 3	Diarrhea Increase < 7 Stools Per Day Over Baseline Incontinence OR Severe Increase in Ostomy Output Compared to Baseline AND Hospitalization Indicated 6	Diarrhea Life-threatening Complications AND Hospitalization Indicated 8

(Continued)

Table 4. (Continued)

Nausea	Nausea Loss of Appetite Without Alteration in Eating Habits 1	Nausea Oral Intake Decreased AND Without Weight Loss, Dehydration, or Malnutrition 2	Nausea Vomiting or Anti-Emetics Required 5	Nausea Inadequate Oral Caloric or Fluid Intake OR Refractory Vomiting with Tube Feed, TPN 7
Vertigo	Vertigo Mild symptoms 3	Vertigo Moderate Symptoms AND Limiting Instrumental Activities Daily Living 5	Vertigo Severe Symptoms AND Limiting Self Care 7	
Vascular Access	Vascular Access Device Dislodgement, Blockage, Leak, Malposition AND Device Replacement Indicated 3	Vascular Access Deep Vein or Cardiac Thrombosis AND Intervention Indicated (e.g. anticoagulation, lysis, filter, invasive procedure) 6	Vascular Access Embolic Event Related to Vascular Access(e.g. pulmonary embolism or life threatening thrombus) 7	
Suicidal Ideation	Suicidal Ideation Increased Thoughts of Death But No Wish to Kill Oneself 7	Suicidal Ideation Suicidal Ideation with No Specific Plan or Intent 7	Suicidal Ideation Specific Plan to Commit Suicide OR Suicide Attempt without Serious Intent to Die May Not Require Hospitalization 10	Suicidal Ideation Suicide Attempt with Intent to Die OR Specific Plan to Commit Suicide with Serious Intent to Die Requires Hospitalization 10
Hallucinations	Hallucinations Mild Hallucinations (e.g. perceptual distortions) 5	Hallucinations Moderate Hallucinations 7	Hallucinations Severe Hallucinations AND Medical Intervention Indicated Hospitalization Not Indicated 7	Hallucinations Life-threatening Complications Threats of Harm to Self or Others AND Hospitalization Indicated 9

(Continued)

Table 4. (Continued)

Sicca	Dry Mouth Symptomatic (e.g. dry thick saliva) AND Without Significant Dietary Alteration	Dry Mouth Moderate Symptoms AND Oral Intake Alterations (e.g. copious water, other lubricants) OR Diet Limited to Purees	Dry Mouth Inadequate Oral Intake AND Tube Feeds, TPN Indicated
	1	3	7
Cushingoid	Cushingoid Mild Symptoms AND Intervention Not Indicated	Cushingoid Moderate Symptoms AND Medical Intervention Indicated	Cushingoid Severe Symptoms AND Medical Intervention or Hospitalization Indicated
	3	6	7
Myalgia	Drug Related Myalgia Mild Pain	Drug Related Myalgia Moderate Pain AND Limiting Instrumental Activities Daily Living	Drug Related Myalgia Severe Pain AND Limiting Self Care Activities Daily Living
	1	5	5
Pruritus	Pruritus (Itching) Mild or Localized AND Topical Intervention Indicated	Pruritus (Itching) Intense or Widespread Intermittent OR Skin Changes from Scratching AND Oral Intervention Indicated	Pruritus (Itching) Intense or Widespread, Constant AND Oral Corticosteroid or Immunosuppressive Therapy Indicated
	1	3	5

(Continued)

Table 4. (Continued)

Dermatologic	Skin Disorders Asymptomatic or Mild Symptoms Clinical or Diagnostic Observations Only 1	Skin Disorders Moderate, Minimal, Local, or Non-Invasive Intervention Indicated 2	Skin Disorders Severe or Medically Significant but Not Immediately Life-Threatening AND Hospitalization or Prolongation of Existing Hospitalization 6	Skin Disorders Life-threatening Consequences AND Urgent Intervention Indicated 7
	Dry Eye Mild symptoms relieved by lubricants 1	Dry Eye Multiple agents indicated to relieve symptoms AND Limiting instrumental activities of daily living 3	Dry Eye Decrease in visual acuity (worse than 20/40) AND Limiting self-care activities of daily living 5	
Constipation	Drug Related Constipation New mild symptoms Occasional use of stool softeners, laxatives, dietary modification, or enema. 1	Drug Related Constipation Persistent symptoms with regular use of laxatives or enemas AND Limiting instrumental activities of daily living 3	Drug Related Constipation <i>Obstipation with manual evacuation indicated</i> AND Limiting self-care activities of daily living 5	Drug Related Constipation <i>Life threatening consequences</i> AND Hospitalization indicated 8
	Injection Site Reaction Tenderness with or without associated symptoms(e.g. warmth, erythema, itching) 2	Injection Site Reaction Pain, Lipodystrophy, Edema, Phlebitis 4	Injection Site Reaction Ulceration or Necrosis with Severe Tissue Damage AND Operative Intervention Indicated 8	Injection Site Reaction Life-threatening consequences AND Urgent intervention indicated 9

(Continued)

Table 4. (Continued)

Falls	Drug Related Fall Minor with no resultant injuries Intervention not indicated 2	Drug Related Fall Symptomatic AND Non-invasive Intervention Indicated 4	Drug Related Fall Hospitalization Indicated 6
Allergic Reaction	Allergic Reaction Transient Flushing AND No Intervention Indicated 1	Allergic Reaction Intervention or Infusion Indicated AND Responds Quickly to Medications Prophylaxis < 24 Hours 4	Allergic Reaction Prolonged (Not rapidly responsive to medical intervention) AND Recurrence of Symptoms Following Medical Treatment Hospitalization Indicated 5
Sexual Dysfunction	Sexual Dysfunction Mild Sexual Dysfunction Not Adversely Affecting Relationship 2	Sexual Dysfunction Moderate Sexual Dysfunction AND Adversely Affecting Relationship 5	Sexual Dysfunction Severe Increase in Sexual Interest Leading to Dangerous Behavior 7
Edema	Edema Limbs Asymptomatic or Mild Symptoms Clinical or Diagnostic Observations Only 3	Edema Limbs Moderate Symptoms AND Minimal, Local, or Non-Invasive Intervention Indicated 4	Edema Limbs Severe or Medically Significant but Not Life- Threatening AND Hospitalization or Prolongation Existing Hospitalization Indicated 8
Fatigue	Fatigue Fatigue Relieved By Rest 2	Fatigue Fatigue Not Relieved by Rest 2	Fatigue Fatigue Not Relieved by Rest AND Limiting Self Care Activities Daily Living 5

(Continued)

Table 4. (Continued)

<i>Anemia</i>	<i>Anemia</i> Hemoglobin (Hgb) < Lower Limit Normal - 10 g/dL OR Hgb < Lower Limits Normal - 6.2mmol/L OR Hgb < Lower Limits Normal - 100g/L	<i>Anemia</i> Hemoglobin (Hgb) < 10- 8 g/dL OR Hgb < 6.2-4.9 mmol/L OR Hgb < 100-80g/L	<i>Anemia</i> Hemoglobin (Hgb) < 8 g/dL OR Hgb < 4.9 mmol/L OR Hgb < 80 g/L AND Transfusion Indicated	<i>Anemia</i> Life-Threatening Consequences AND Urgent Intervention Indicated	3 4 9
<i>DIC</i>	<i>Disseminated Intravascular Coagulation</i> Lab Findings with No Bleeding	<i>Disseminated Intravascular Coagulation</i> Lab Findings with Bleeding	<i>Disseminated Intravascular Coagulation</i> Life-Threatening Consequences AND Hospitalization and Urgent Intervention Indicated		5 8 10 9
<i>Dyskinesia</i>	<i>Dyskinesia</i> Mild Restlessness or Increased Motor Activity	<i>Dyskinesia</i> Moderate Restlessness or Increased Motor Activity AND Limiting Instrumental Activities Daily Living	<i>Dyskinesia</i> Severe Restlessness or Increased Motor Activity AND Limiting Self Care Activities Daily Living		5 8 8
<i>Kidney Stones</i>	<i>Renal Calculi (Kidney Stones)</i> Asymptomatic of Mild Symptoms AND Occasional Use of Non-Prescription Agents	<i>Renal Calculi (Kidney Stones)</i> Symptomatic AND Oral Anti-emetics OR Around the Clock Non-Prescription Analgesics or Any Oral Narcotic	<i>Renal Calculi (Kidney Stones)</i> Hospitalization Indicated AND IV Intervention Elective Endoscopic or Radiographic Intervention Indicated	<i>Renal Calculi (Kidney Stones)</i> Life-Threatening Complications AND Urgent Endoscopic or Operative Intervention and Hospitalization Indicated	3 6 7 9

(Continued)

Table 4. (Continued)

Insomnia	Insomnia Mild Difficulty Falling Asleep, Staying Asleep, or Waking Up Early 3	Insomnia Moderate Difficulty Falling Asleep, Staying Asleep, or Waking Up Early 3	Insomnia Severe Difficulty Falling Asleep, Staying Asleep, or Waking Up Early 6
Pancreatitis	Pancreatitis Enzyme Elevation or Radiologic Findings Only 3	Pancreatitis Severe Pain, Vomiting AND Medical Intervention Indicated (e.g. analgesia, nutritional support) 8	Pancreatitis Life-Threatening Consequences AND Hospitalization and Urgent Intervention Indicated 9
Flu Reaction	Flu Like Symptoms Mild Flu-Like Symptoms 2	Flu Like Symptoms Moderate Flu-Like Symptoms > 1 day 2	Flu Like Symptoms Severe Flu-Like Symptoms > 1 Day AND Limiting Self Care Activities Daily Living 5
Gait Dysfunction	Gait Disturbance Mild Change in Gait (e.g. wide based, limping, or hobbling) 4	Gait Disturbance Moderate Change in Gait (e.g. wide based, limping, or hobbling) AND Assistive Device Indicated 4	Gait Disturbance Severe Change in Gait AND Disabling Requires Wheelchair 8
Febrile Neutropenia	Febrile Neutropenia ANC < 1000/mm ³ with Single Temp > 38.3C (101F) OR Sustained Temp > /= 38C (100.4) for more than 1 Hour 6	Febrile Neutropenia Life-Threatening Consequences AND Hospitalization and Urgent Intervention Indicated 8	
Laboratory Abnormalities			

(Continued)

Table 4. (Continued)

INR Elevation	INR Increase INR > 1–1.5 x Upper Limit Normal OR INR > 1–1.5 x Above Baseline if on Anticoagulation	INR Increase INR > 1.5–2.5 x Upper Limit Normal OR INR > 1.5–2.5 x Above Baseline if on Anticoagulation	INR Increase INR > 2.5 x Upper Limit Normal OR INR > 2.5 x Above Baseline if on Anticoagulation	
ALT/AST Elevation	ALT or AST Elevation Lab 2–3 x Upper Limit Normal	ALT or AST Elevation Lab 3–5 x Upper Limit Normal	ALT or AST Elevation Lab 5–20 x Upper Limit Normal	ALT or AST Elevation Lab > 20 x Upper Limit Normal
Neutropenia	Neutrophil Count Reduced ANC < Lower Limit Normal - 1500/mm ³ OR ANC < Lower Limit Normal - 1.5 x 10e ⁹ /L	Neutrophil Count Reduced ANC < 1500–1000/mm ³ OR ANC < 1.5–1 x 10e ⁹ /L	Neutrophil Count Reduced ANC < 1000–500/mm ³ OR ANC < 1–0.5 x 10e ⁹ /L	Neutrophil Count Reduced ANC < 500/mm ³ OR ANC < 0.5 x 10e ⁹ /L
Low Platelets	Platelet Count Reduced Platelets < Lower Limit Normal - 75,000/mm ³ OR Platelets < Lower Limit Normal - 75 x 10e ⁹ /L	Platelet Count Reduced Platelets < 75,000–50,000/mm ³ OR Platelets < 75–50 x 10e ⁹ /L	Platelet Count Reduced Platelets < 50,000–25,000/mm ³ OR Platelets < 50–25 x 10e ⁹ /L	Platelet Count Reduced Platelets < 25,000/mm ³ OR Platelets < 25 x 10e ⁹ /L
Hypnatremia	Hypnatremia Na > Upper Limit Normal - 150 mmol/L	Hypnatremia Na > 150–155 mmol/L	Hypnatremia Na > 155–160 mmol/L AND Hospitalization Indicated	Hypnatremia Na > 160 mmol/L and Life Threatening Consequences Hospitalization Indicated
	4	6	6	7
	3	4	7	8
	3	4	7	8
	4	6	6	7
	3	3	7	7

(Continued)

Table 4. (Continued)

Hyponatremia	Hyponatremia Na < 130 mmol/L - Lower Limit Normal	Hyponatremia Na < 120–130 mmol/L	Hyponatremia Na < 120 mmol/L Life Threatening Complications	Hyponatremia Na < 120 mmol/L Life Threatening Complications
Hypokalemia	Hypokalemia K < 3 mmol/L - Lower Limit Normal	Hypokalemia K < 3 mmol/L - Lower Limit Normal AND Symptomatic Intervention Indicated	Hypokalemia K < 2.5–3 mmol/L AND Hospitalization Indicated	Hypokalemia K < 2.5 mmol/L with Life Threatening Consequences AND Urgent Hospitalization
Hyperkalemia	Hyperkalemia K > Upper Limits Normal - 5.5 mmol/L	Hyperkalemia K > 5.5–6 mmol/L	Hyperkalemia K > 6–7 mmol/L	Hyperkalemia K > 7 mmol/L
Reproductive and Congenital Complications	Reproductive System Disorder (Adult Male/Female) Asymptomatic or mild symptoms Clinical or Diagnostic Observations Only Intervention not indicated	Reproductive System Disorders Moderate AND Minimal, Local, or Non-Invasive Intervention	Reproductive System Disorders Severe AND Hospitalization or Prolongation of Existing Hospitalization	Reproductive System Disorders Life-threatening Consequences AND Urgent Intervention Indicated
	2	3	8	9
	2	6	8	5

(Continued)

Table 4. (Continued)

Congenital Abnormalities	<p>Minor Physical Congenital Abnormalities with No Clinical Significance (e.g. single palmar crease, pre-auricular skin tag)</p>	<p>Intrauterine Growth Restriction: Birth weight below 10th percentile for gestational age. Requires additional monitoring. May have clinical consequences.</p>	<p>Physical Features Persisting in a Term Infant that are Typically Only Present Before 37 Weeks Gestation (e.g. patent ductus arteriosus, undescended testicle)</p>	<p>Genetic Disorders: Genetic disorders compatible with survival but likely to result in disability. (e.g. Chromosomal Disorders, Trisomy 21)</p>	<p>Facial/Orthopaedic Sequelae: Hypoplasia of face or fingers, Arthrogryposis, Loss of Limb</p>	<p>Microcephaly/Macrocephaly: Abnormalities in head circumference and brain size. Requires additional monitoring. May result in cognitive dysfunction.</p>	<p>Major Cardiac, Pulmonary, Gastrointestinal Malformations: Structural abnormality with surgical or medical importance. (e.g. major cyanotic heart disease, esophageal atresia, gastroschisis)</p>
3		8	6	10	10	10	10
Spina Bifida	<p>Closed Spinal Dysraphism (i.e. spina bifida occulta): Failure of fusion of vertebral bodies. Unexposed neural tissue. Skin Intact.</p>	<p>Myelomeningocele: Cleft in vertebral column</p>	<p>Encephalocele: Protrusion of brain and/or meninges through skull. Covered by skin. AND May be compatible with survival but with likely disability.</p>	<p>Anencephaly: Open deficit; cranial tube exposed. Not compatible with survival.</p>			
8		9	10	10			

(Continued)

Table 4. (Continued)

Teratogenicity	Teratogenic Mild Intellectual Disability:	Teratogenic Moderate Intellectual Disability:	Teratogenic Severe Intellectual Disability:	Teratogenic Profound Intellectual Disability:
<p>Children require academic supports to learn skills appropriate for age. Social skills and personal judgment immature for age. Most individuals independent in daily living activities, employable in jobs, and able to live independently.</p>	<p>Conceptual and academic skills lag well behind peers. Adults able attain elementary level skills. Social cues, judgment, and life decisions require support. Most capable of personal care with support (e.g. group home).</p>	<p>Little understanding of written language, numbers, time, money concepts. Caretakers provide extensive support. Benefit from interaction with family/familiar people with limited social interaction. Trainable in some basic activities of daily living.</p>	<p>May use objects in a goal directed fashion for self-care or recreation. May understand some gestures and emotional cues. Dependent on support for all activities of daily living.</p>	
9	10	10	10	

<https://doi.org/10.1371/journal.pone.0262109.t004>

had an AEU score of 6 and Severe Hallucinations/Medical Intervention Indicated (Hospitalization Not Indicated) had an AEU score of 5. This likely occurred as physicians were not shown the full range of side effects in each category when assigning scores. We did not show physicians all the AEs in a category to reduce survey burden and to prevent bias from being shown a group of side effects in a previously determined, ordinal fashion. In these three circumstances after discussion among the investigators, the decision was made to rate both categories with the higher AEU score prior to obtaining potential patient input; e.g. both hallucination categories in question have a final AEU score of 6. This decision is also supported by overlap in the interquartile range of these categories in the original physician subject weighted values.

Discussion

In the age of precision medicine, well-designed, practical outcome measures and decision support tools expand the data we track about patients to better inform medical decisions [33, 34]. Unlike previous measures, the physician and potential patient derived AEU quantifies AE burden in a common currency independent of any disease or medication class, that can be compared among different medications over time. The AEU may facilitate movement from more gestalt AE burden measurement to more precise AE burden measurement, enriching treatment discussions between patients and physicians.

Individual patients and physicians may not value AE in the same way, e.g. patients with more severe conditions such as cancer, may tolerate a higher burden of AE. As a consensus metric, the AEU is not designed to be an absolute measure of burden and distress for any particular patient but rather a way to keep the AE burden score. The AEU is designed to best estimate the market price of specific AEs, similarly to how the price is set for a good or service, e.g. \$10 for a basketball and \$30,000 for a car. Consumers decide if they are willing to pay consensus prices for these goods. Similarly, patients can be given AEU scores corresponding to the number and type of AEs they develop on a given therapy. In combination with measures of disease improvement, financial burden, overall QOL, severity of a patient's medical condition, patient age, and other factors unique to a particular patient, patients can decide whether they are willing to tolerate a specific AEU burden when making treatment decisions with their physician. Future validation projects, like one underway in a population of patients with myasthenia gravis, will attempt to understand clinically meaningful differences in AEU score over time for different patient populations.

Attempts have been made to develop disease and medication specific measures of AE [8–13]. Disease and medication specificity limit broad applicability. Quality Adjusted Life Year (QALY) is a useful measure of population cost effectiveness of varied treatments [35, 36]. Since the QALY encompasses all aspects of health, financial cost, and QOL, it cannot measure AE burden alone. As a population based tool, the QALY is a less practical way to measure treatment burden in a comparative efficacy trial or in the clinic.

The CTCAE is a medication independent, physician derived AE measurement tool [21]. Due to lack of weighting and patient input, it provides only granular AE burden measurement. We built the AEU based on the strengths of the CTCAE. The diverse physician group incorporated a wide range of opinions about AE impact on overall health accounting for both current effects (e.g. joint pain) as well as future secondary consequences (e.g. stroke due to new diabetes) to assign AEU values. Although all physicians surveyed could rate congenital complication AEs, all pediatricians surveyed weighted these items as they care for impacted children.

The AEU incorporates potential patient opinions in assigning AE burden values. The use of potential patients rather than patients with particular diagnoses allows AE burden to be scored

independent of any particular disease or medication. While we were not able to stratify the sample by whether MTurk respondents were parents, many subjects who rated congenital AEs self-identified as parents in the comment section. Since MTurk doesn't permit stratification by ethnicity, some groups were slightly underrepresented in our sample. We observed even representation of U.S. geographic regions. Utilizing MTurk, we obtained hundreds of opinions within days of survey release. Although MTurk introduced bias due to requirement of basic computing skills, it reduced other bias, including the selection bias of clinicians when choosing patients for participation in research. We found recruitment through this online tool to be a logistical and cost-effective strategy to easily obtain opinions from large samples. This method has the potential to be a powerful method for studies like this one and to obtain preliminary data for clinical study design while reducing the inherent bias of the small focus group method.

We believe the weighted consensus AEU values provides a more complete measurement of AE burden. A CTCAE category 1 is often classified as mild [37]. However, all CTCAE categories across different AEs are not of equal value and were not weighted the same among our cohort. A CTCAE grade 1 may not reflect a good outcome in all circumstances. For example, CTCAE Grade 1 pulmonary fibrosis, received an AEU score of 7 and was rated the same as CTCAE Grade 4 osteoporosis (Table 4). We also believe the AEU's independence of any particular disease or medication class is essential to allow comparison of treatments across medication classes. For example, prednisone and IVIG, treatments with different AE profiles, could be compared by the AEU in patients with myasthenia gravis.

Although 75% of AE categories required final AEU value adjustment when physician and potential patient values were combined, only 12% of items had a rating difference of 3 or more points between physicians and potential patients (Table 4). This suggests that while there is difference in physician and potential patient opinions on AE severity, there appears to be general agreement among the groups. Use of the Bradley-Terry paired comparisons model was a useful way to put the physician ratings, collected as scores, and the MTurk ratings, collected as a sequence of paired comparisons, on the same scale. Although physician opinions anchored AEU values, potential patient opinions were incorporated via the discrete choice surveys. We believe adjusting the AEU score to incorporate opinions of both groups strengthens the future applicability of this tool. In practice, patients often rely on physician expert caregivers to guide medical decisions.

We believe the AEU has great promise to be a useful, practical tool to add precision to AE burden measurement in the clinic and in comparative efficacy research for neurology patients. Future studies may show the AEU to be useful in other medical specialties. In comparative efficacy research, we anticipate that AE burden of drugs from different classes can be compared by AEU burden. Assigning an AEU score over time will account for more transient AEs that drop out over time (e.g. single headache) and more persistent AEs (e.g. new hypertension). The AEU score can be combined with other disease specific outcome metrics and QOL metrics to measure differences among medications over time. Evaluation of the validity, utility, and value of the AEU in comparative efficacy trials in myasthenia gravis and other neurological disorders is under way. If the AEU is useful in these studies, translation of some or all of the other items in the CTCAE could be performed to generalize the AEU to other medical subspecialties.

Supporting information

S1 File.
(DOCX)

S2 File. Physician subject raw data form 2.
(CSV)

S3 File. All potential patient choices raw data.
(XLSX)

S4 File. Physician subject raw data form 5.
(CSV)

S5 File. AEU item codes raw data.
(XLSX)

S6 File. Physician subject raw data form 1.
(CSV)

S7 File. Physician subject raw data pediatric form.
(CSV)

S8 File. Physician subject raw data form 6.
(CSV)

S9 File. Physician subject raw data form 4.
(CSV)

S10 File. Physician subject raw data form 3.
(CSV)

Acknowledgments

Dr. Robert Shapiro, Professor of Neurological Sciences at the University of Vermont Larner College of Medicine, provided the idea to utilize the Amazon Mechanical Turk program for this study. The authors are indebted to the 363 physicians who completed the surveys for this project without compensation.

Author Contributions

Conceptualization: Michael K. Hehir, Eric M. Clark, Denise B. Aronzon, Reza Sadjadi, Ted M. Burns.

Data curation: Michael K. Hehir, Mark Conaway, Eric M. Clark, Denise B. Aronzon, Noah Kolb, Amanda Kolb, Katherine Ruzhansky, Eduardo A. De Sousa.

Formal analysis: Michael K. Hehir, Mark Conaway, Ted M. Burns.

Funding acquisition: Michael K. Hehir.

Investigation: Michael K. Hehir, Mark Conaway, Noah Kolb, Amanda Kolb, Katherine Ruzhansky, Eduardo A. De Sousa, Ted M. Burns.

Methodology: Michael K. Hehir, Mark Conaway, Denise B. Aronzon, Ted M. Burns.

Project administration: Michael K. Hehir.

Resources: Michael K. Hehir.

Software: Michael K. Hehir, Eric M. Clark.

Writing – original draft: Michael K. Hehir, Mark Conaway, Ted M. Burns.

Writing – review & editing: Michael K. Hehir, Eric M. Clark, Denise B. Aronzon, Noah Kolb, Amanda Kolb, Katherine Ruzhansky, Reza Sadjadi, Eduardo A. De Sousa.

References

1. Smith AG. The Cost of Rare Diseases is Threatening the U.S. Health Care System. *Harvard Business Review*. 2017.
2. Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schroder R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. *Journal of neurology*. 2010; 257(1):15–23. <https://doi.org/10.1007/s00415-009-5256-6> PMID: 19629566
3. Guptill JT, Marano A, Krueger A, Sanders DB. Cost analysis of myasthenia gravis from a large U.S. insurance database. *Muscle & nerve*. 2011; 44(6):907–11. <https://doi.org/10.1002/mus.22212> PMID: 22102461
4. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. *JAMA: the journal of the American Medical Association*. 1997; 277(4):301–6. PMID: 9002492
5. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. *JAMA: the journal of the American Medical Association*. 1997; 277(4):307–11. PMID: 9002493
6. Quality AfHRa. Reducing and Preventing Adverse Drug Events to Decrease Hospital Costs. <https://archiveahrq.gov/research/findings/factsheets/errors-safety/aderia/adehtml>. 2001.
7. Martinez-Ramirez D, Giugni JC, Little CS, Chapman JP, Ahmed B, Monari E, et al. Missing dosages and neuroleptic usage may prolong length of stay in hospitalized Parkinson's disease patients. *PloS one*. 2015; 10(4):e0124356. <https://doi.org/10.1371/journal.pone.0124356> PMID: 25884484
8. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. *The New England journal of medicine*. 1993; 328(13):907–13. <https://doi.org/10.1056/NEJM199304013281302> PMID: 8446137
9. Katz NP, Mou J, Trudeau J, Xiang J, Vorsanger G, Orman C, et al. Development and preliminary validation of an integrated efficacy-tolerability composite measure for the evaluation of analgesics. *Pain*. 2015; 156(7):1357–65. <https://doi.org/10.1097/j.pain.0000000000000186> PMID: 25867124
10. Mohr DC, Likosky W, Boudewyn AC, Marietta P, Dwyer P, Van der Wende J, et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. *Multiple sclerosis*. 1998; 4(6):487–9. <https://doi.org/10.1177/135245859800400605> PMID: 9987757
11. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. *Schizophrenia research*. 2000; 43(2–3):135–45. [https://doi.org/10.1016/s0920-9964\(99\)00154-1](https://doi.org/10.1016/s0920-9964(99)00154-1) PMID: 10858632
12. Smith SM, Wang AT, Katz NP, McDermott MP, Burke LB, Coplan P, et al. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTION systematic review and recommendations. *Pain*. 2013; 154(7):997–1008. <https://doi.org/10.1016/j.pain.2013.03.003> PMID: 23602344
13. Hunsinger M, Smith SM, Rothstein D, McKeown A, Parkhurst M, Hertz S, et al. Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTION systematic review. *Pain*. 2014; 155(11):2253–62. <https://doi.org/10.1016/j.pain.2014.08.004> PMID: 25123543
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of biomedical informatics*. 2009; 42(2):377–81. <https://doi.org/10.1016/j.jbi.2008.08.010> PMID: 18929686
15. Behrend TS, Sharek DJ, Meade AW, Wiebe EN. The viability of crowdsourcing for survey research. *Behavior research methods*. 2011; 43(3):800–13. <https://doi.org/10.3758/s13428-011-0081-0> PMID: 21437749
16. Goodman JK CC, Cheema A. Data collection in a flat world: the strengths and weaknesses of mechanical turk samples. *Journal of Behavioral Decision Making*. 2013; 26:213–24.
17. Schmidt GB, Jettinghoff WM. Using Amazon Mechanical Turk and other compensated crowdsourcing sites. *Bus Horizons*. 2016; 59(4):391–400.
18. Paolacci G, Chandler J. Inside the Turk: Understanding Mechanical Turk as a Participant Pool. *Current Directions in Psychological Science*. 2014; 23(3):184–8.

19. Buhrmester M, Kwang T, Gosling SD. Amazon's Mechanical Turk: A New Source of Inexpensive, Yet High-Quality, Data? *Perspectives on psychological science: a journal of the Association for Psychological Science*. 2011; 6(1):3–5. <https://doi.org/10.1177/1745691610393980> PMID: 26162106
20. Bernstein J, Calamia M. Characteristics of a Mild Traumatic Brain Injury Sample Recruited Using Amazon's Mechanical Turk. *PM & R: the journal of injury, function, and rehabilitation*. 2017. <https://doi.org/10.1016/j.pmrj.2017.06.010> PMID: 28633999
21. Institute NC. Common Terminology Criteria for Adverse Events v4.0. NIH Publication 09–7473. 2009.
22. Association AP. Neurodevelopmental Disorders. *Diagnostic and statistical manual of mental disorders (5th ed)* 2013.
23. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity of anticonvulsant drugs. *The New England journal of medicine*. 2001; 344(15):1132–8. <https://doi.org/10.1056/NEJM200104123441504> PMID: 11297704
24. Copp AJ, Stanier P, Greene ND. Neural tube defects: recent advances, unsolved questions, and controversies. *The Lancet Neurology*. 2013; 12(8):799–810. [https://doi.org/10.1016/S1474-4422\(13\)70110-8](https://doi.org/10.1016/S1474-4422(13)70110-8) PMID: 23790957
25. Greene ND, Copp AJ. Neural tube defects. *Annual review of neuroscience*. 2014; 37:221–42. <https://doi.org/10.1146/annurev-neuro-062012-170354> PMID: 25032496
26. Burns TM, Conaway MR, Cutter GR, Sanders DB, Muscle Study G. Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite. *Muscle & nerve*. 2008; 38(6):1553–62. <https://doi.org/10.1002/mus.21185> PMID: 19016543
27. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. *The Lancet Oncology*. 2006; 7(11):903–9. [https://doi.org/10.1016/S1470-2045\(06\)70910-X](https://doi.org/10.1016/S1470-2045(06)70910-X) PMID: 17081915
28. Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. *Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2013; 16(1):3–13.
29. Louviere JL, Flynn T.N., and Carson R.T. Discrete Choice Experiments and Not Conjoint Analysis. *Journal of Choice Modelling*. 2010; 3(3):57–72.
30. Firth D. Bias reduction of maximum likelihood estimates. *Biometrika*. 1993; 80(1):27–38.
31. Hunter D. MM Algorithms for Generalized Bradley-Terry Models. *Annals of Statistics*. 2004; 32(1):384–406.
32. Bureau USC. Race and Hispanic Origin 2010 [Available from: <https://www.census.gov/quickfacts/fact/table/US/PST045217#qf-headnote-a>].
33. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. *The New England journal of medicine*. 2012; 366(6):489–91. <https://doi.org/10.1056/NEJMp1114866> PMID: 22256780
34. Burns TM. The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis. *Muscle & nerve*. 2016; 53(1):3–4. <https://doi.org/10.1002/mus.24953> PMID: 26506220
35. Bravo Vergel Y, Sculpher M. Quality-adjusted life years. *Practical neurology*. 2008; 8(3):175–82. <https://doi.org/10.1136/pn.2007.140186> PMID: 18502950
36. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. *Health policy and planning*. 2006; 21(5):402–8. <https://doi.org/10.1093/heapol/czl018> PMID: 16877455
37. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016; 87(4):419–25. <https://doi.org/10.1212/WNL.0000000000002790> PMID: 27358333